136 results
8-K
EX-10.2
1cuqwu9t
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
gn43xejn
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
hn1i4mo9
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
0cui85x9
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
wgr1jt
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
fc9nig2
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
j07hs
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
51p2630ubgp8wi11dp5e
30 May 23
Business combination disclosure
4:21pm
8-K
lizyu6xk
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
1g4ht5sa6qf x1
22 May 23
Business combination disclosure
7:01am
8-K
rpn9evzhxhr3j6nhe
22 May 23
Other Events
6:59am
8-K
EX-99.1
aut 553b14xu6x
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
jeooyw
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
gd2af8uvg6tg bjijeik
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm